Skip to main
PTHS

PTHS Stock Forecast & Price Target

PTHS Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pelthos Therapeutics Inc is experiencing a significant growth trajectory, marked by an impressive 41% sequential increase in prescriptions in October, which exceeded the volume recorded in the entire third quarter. This momentum is backed by an expanding sales force, set to grow from 50 to 64 territory managers targeting approximately 10,000 clinicians, positioning the company for broader market penetration. Furthermore, the upward revision of net revenue projections for 4Q25 to $16.2 million from $4.5 million underscores the strong market demand for its therapeutics and the potential for Pelthos to solidify its revenue base through effective commercial strategies.

Bears say

The negative outlook on Pelthos Therapeutics's stock is primarily attributed to significant risks surrounding its pipeline products, which may fail to deliver statistically significant results in late-stage clinical trials or gain approval from regulatory bodies, thereby diminishing the overall value of the company. Additionally, inadequate reimbursement levels, formulary placement, or slow adoption among healthcare providers may lead to lower-than-expected revenue growth, further impacting projected sales and margins. Furthermore, competitive pressures from existing and emerging products in the market could restrict Pelthos's ability to capture market share and achieve anticipated revenue levels.

PTHS has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pelthos Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pelthos Therapeutics Inc (PTHS) Forecast

Analysts have given PTHS a Strong Buy based on their latest research and market trends.

According to 5 analysts, PTHS has a Strong Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pelthos Therapeutics Inc (PTHS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.